CCL5 and inflammatory bowel disease: Therefore, blockade of the CCL5:CCR5 axis seems to be a viable therapeutic avenue for IBD, and a previously described potent CCR5 antagonist (CCL5 5p12 5m) (24) may turn instrumental to this aim.